Kuros Biosciences AG (0RHR)
Market Closed
8 Dec, 15:30
LSE 
SIX Primary LSE 30. 15
CHF -0.99
-3.16%
- Market Cap
- P/E Ratio
0% Div Yield
13,069 Volume
0 Eps
31.14 CHF
Previous Close Day Range
30.04 30.94
Year Range
1.33 30.94
Want to track 0RHR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
0RHR closed today lower at 30.15 CHF, a decrease of 3.16% from yesterday's close, completing a monthly increase of 12.52% or 3.35 CHF. Over the past 12 months, 0RHR stock gained 40.26%.
0RHR is not paying dividends to its shareholders.
The last earnings report, released on Aug 13, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Kuros Biosciences AG has completed 1 stock splits, with the recent split occurring on Jun 23, 2016.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on SIX (CHF).
0RHR Chart
Kuros Biosciences AG (0RHR) FAQ
What is the stock price today?
The current price is 30.15 CHF.
On which exchange is it traded?
Kuros Biosciences AG is listed on SIX.
What is its stock symbol?
The ticker symbol is 0RHR.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, no market cap data is available.
Has Kuros Biosciences AG ever had a stock split?
Kuros Biosciences AG had 1 splits and the recent split was on Jun 23, 2016.
Kuros Biosciences AG Profile
| Biotechnology Industry | Healthcare Sector | Mr. Christopher T. Fair CEO | LSE Exchange | CH0325814116 ISIN |
| CH Country | 80 Employees | - Last Dividend | 23 Jun 2016 Last Split | - IPO Date |
Overview
Kuros Biosciences AG is a distinguished biopharmaceutical entity focusing on the forefront of tissue repair and bone regeneration, extending its innovative solutions across the United States, the European Union, and other global territories. Founded in 2016 and with its headquarters nestled in Schlieren, Switzerland, the company carves its niche through three operational segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. Its commitment to advancing the standards of care in bone regeneration and repair is reflected in its robust product lineup and its active engagement in clinical trials aimed at exploring new therapeutic frontiers.
Products and Services
- MagnetOs Granules: This flagship product is an advanced bone graft distinguished by its NeedleGrip surface technology, which is characterized by submicron needle-shaped structures. Designed to foster bone regeneration, MagnetOs Granules set a high bar in the domain of skeletal repair.
- MagnetOs Putty: As a versatile mold, MagnetOs Putty fills bony voids to ensure predictable fusion. It underscores the company's commitment to providing adaptable solutions for complex bone regeneration needs.
- MagnetOs Easypack Putty: Tailored for convenience, this ready-to-use mold can be implanted in any intervertebral disc space or posterolateral spine level. Its design philosophy revolves around ease of use without compromising on efficacy, catering to the dynamic requirements of spinal surgeries.
- Magnetos Flex Matrix: This product emerges as an open matrix bone graft, embodying the company's innovative approach towards creating flexible, yet robust frameworks for bone regeneration. It represents a stride towards versatility and effectiveness in tissue repair technologies.
- Fibrin-PTH pipeline products (KUR-111 and KUR-113): These are ground-breaking developments in the company's pharmaceutical segment, currently explored in Phase 2b clinical trials for trauma indications. Additionally, KUR-113 has entered Phase 2a clinical trials for spinal indications. These products exemplify Kuros Biosciences' relentless pursuit of novel therapies to address complex medical needs.
Contact Information
Address: Wagistrasse 25, Schlieren, Switzerland, 8952
Phone: 41 44 733 4747
Website: https://www.kuros.ch
2025 © Marketlog. All Rights Reserved.
